Alumis Inc
Clinical trials sponsored by Alumis Inc, explained in plain language.
-
Psoriasis drug ESK-001 tested for Long-Term safety in extension study
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug ESK-001 in people with plaque psoriasis who have already completed an earlier ESK-001 study. About 165 adults will take the drug for an extended period to track side effects and see how well it controls psoria…
Phase: PHASE2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated May 26, 2026 05:54 UTC
-
Psoriasis drug ESK-001 tested for Long-Term safety and effectiveness
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug ESK-001 in adults with moderate to severe plaque psoriasis. Participants must have completed a prior ESK-001 study. They will take ESK-001 twice daily for 24 weeks, then some may switch to a placebo to see if …
Phase: PHASE3 • Sponsor: Alumis Inc • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New lupus drug shows promise in phase 2 trial
Disease control OngoingThis study tests an experimental drug called ESK-001 in adults with lupus (SLE). The goal is to see if it can reduce disease activity better than a placebo over 48 weeks. About 408 participants who have active lupus and are on standard treatments will receive either ESK-001 or a …
Phase: PHASE2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated May 18, 2026 12:01 UTC